ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Hot Features

Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

IMNN Imunon Inc

1,51
0,01 (0,67%)
09 Mai 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Imunon Inc IMNN NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
0,01 0,67% 1,51 21:00:00
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
1,53 1,43 1,57 1,51 1,50
mais cotações »

Notícias Recentes

Data Hora Fonte Título
08/05/202409:00GLOBEIMUNON Appoints Director Dr. Stacy R. Lindborg as President..
06/05/202412:00GLOBEIMUNON to Hold First Quarter 2024 Financial Results and..
18/04/202409:30GLOBEIMUNON’s IND Application Cleared to Begin Human Testing of..
11/04/202409:00GLOBEIMUNON Reports Compliance with Nasdaq Listing Requirements
28/03/202409:00GLOBEIMUNON Reports 2023 Financial Results and Provides Business..
25/03/202409:30GLOBEIMUNON Receives $1.3 Million from Sale of its New Jersey Net..
21/03/202418:00GLOBEIMUNON to Hold 2023 Financial Results and Business Update..
13/03/202409:00GLOBEIMUNON Files IND Application to Begin Human Testing of..
12/03/202418:00GLOBEIMUNON Announces Leadership Change
29/02/202410:30GLOBEIndependent Lab Confirms Immunogenicity and Protection with..
27/02/202410:30GLOBEMemorial Sloan Kettering Cancer Center Now Enrolling..
22/02/202410:00GLOBEIMNN-101 Preclinical Data in SARS CoV-2 Published in..
11/12/202310:30GLOBEIMUNON Appoints Dr. Sebastien Hazard as Chief Medical..
14/11/202311:00GLOBEIMUNON’s VP of R&D to Present at the Vaccines Summit-2023
14/11/202310:00GLOBEIMUNON Reports Third Quarter 2023 Financial Results and..
07/11/202310:30GLOBEIMUNON to Hold Third Quarter 2023 Financial Results and..
23/10/202309:30GLOBEIMUNON’s Chief Science Officer to Present at the 3rd..
19/10/202309:30GLOBEIMUNON CEO Dr. Corinne Le Goff to Participate in a Panel..
18/10/202309:30GLOBEIMUNON Announces First Patient enrolled in Phase 1/2..
06/10/202309:30GLOBEIMUNON Appoints Dr. Patrick Ott to its Scientific Advisory..
28/09/202309:30GLOBEIMUNON Reports Interim Progression-Free Survival and Overall..
26/09/202309:30GLOBEIMUNON Releases Enterprise Video Highlighting the Company’s..
13/09/202309:30GLOBEIMUNON Reminds Investors of its Virtual R&D Day Tomorrow at..
07/09/202317:30GLOBEIMUNON to Host Virtual R&D Day on September 14th Beginning..
05/09/202309:30GLOBEIMUNON to Participate in the H.C. Wainwright Global..
24/08/202317:05GLOBEIMUNON Enters into CRADA for Preclinical Studies of PlaCCine..
14/08/202309:30GLOBEIMUNON Expands Scientific Advisory Board with the Addition..
10/08/202309:00GLOBEIMUNON Reports Second Quarter 2023 Financial Results and..
07/08/202309:30GLOBEPreclinical Data Showing Strong Immunogenicity and..
03/08/202309:30GLOBEIMUNON to Hold Second Quarter 2023 Financial Results and..
27/06/202313:00GLOBEIMUNON Unveils New Manufacturing Capabilities at..
26/06/202318:00GLOBEImunon Reports Inducement Grants under NASDQ Listing Rule..
12/06/202309:30GLOBEIMUNON CEO to Discuss Company’s Novel Non-viral DNA Therapy..
08/06/202309:30GLOBEIMUNON’s CEO Presents Business Overview to Investors and..
30/05/202309:00GLOBEIMUNON Presents PlaCCine Preclinical Data at the 2023..
11/05/202309:00GLOBEIMUNON Reports First Quarter 2023 Financial Results and..

Seu Histórico Recente

Delayed Upgrade Clock